Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...
It’s a good day to be the pharmaceutical giant Eli Lilly. Right now, Eli Lilly appears to be the leader in the GLP-1 race amid multiple difficult headwinds for Novo Nordisk. As of this writing, Novo ...
Eli Lilly LLY0.80%increase; green up pointing triangle received approval from the Food and Drug Administration for a label expansion of its weight-loss drug Zepbound, adding a new monthly delivery ...
Novo Nordisk announced its CagriSema GLP-1 weight loss drug underperformed Eli Lilly's tirzepatide in a trial. Separately, Lilly announced patients can use a single injector to hold a month's supply ...
In the lucrative obesity drug race, there is Eli Lilly — and then there's everybody else. A pair of headlines Monday reinforced Lilly's dominance: Its lone commercial rival, Novo Nordisk , released ...
White appears to be the top internal candidate to replace Jurickson Profar (suspension) as a platoon partner for Mike Yastrzemski in left field, Gabriel Burns of the Atlanta Journal-Constitution ...
Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this ...
Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...
Former NFL quarterback Eli Manning gifted Pro Football Hall of Fame quarterback Peyton Manning a custom portrait featuring every defender who intercepted Peyton during his rookie season where he threw ...
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead.
LONDON, Feb 24 (Reuters) - With U.S. arch rival Eli Lilly (LLY.N), opens new tab streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk (NOVOb.CO), opens new tab needed ...
Novo Nordisk shares sank after the Danish drugmaker suffered a setback in its battle with Eli Lilly to dominate the market for weight-loss drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results